TBK1-IN-1

• CAT Number: I042353
• Molecular Formula: C27H35N7O2
• Molecular Weight: 489.61
• Purity: ≥95%
• Synonyms: N-[3-[2-[3-[(4-acetylpiperazin-1-yl)methyl]anilino]pyrrolo[2,3-d]pyrimidin-7-yl]propyl]cyclobutanecarboxamide
• InChI: InChI=1S/C27H35N7O2/c1-20(35)33-15-13-32(14-16-33)19-21-5-2-8-24(17-21)30-27-29-18-23-9-12-34(25(23)31-27)11-4-10-28-26(36)22-6-3-7-22/h2,5,8-9,12,17-18,22H,3-4,6-7,10-11,13-16,19H2,1H3,(H,28,36)(H,29,30,31)
• InChIKey: QVADRMQCYNOPPE-UHFFFAOYSA-N
• SMILES: CC(=O)N1CCN(CC1)CC2=CC(=CC=C2)NC3=NC=C4C=CN(C4=N3)CCCNC(=O)C5CCC5

TBK1-IN-1 (Cat No.: I042353) is a selective small-molecule inhibitor of TANK-binding kinase 1 (TBK1), a serine/threonine kinase involved in innate immune signaling, inflammation, and autophagy. By blocking TBK1 activity, TBK1-IN-1 disrupts phosphorylation of IRF3 and downstream production of type I interferons and pro-inflammatory cytokines. This inhibitor is a valuable tool for studying TBK1’s role in antiviral responses, cancer, and neuroinflammatory disorders such as ALS. TBK1-IN-1 aids in the development of targeted therapies modulating aberrant immune and inflammatory signaling pathways.

Reference

[1]. Vassilev LT, et, al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004 Feb 6;303(5659):844-8.
[Content Brief]